Published in Per Med on January 01, 2010
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (1994) 9.06
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
Mechanisms of thrombus formation. N Engl J Med (2008) 4.67
Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med (1993) 4.66
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol (2008) 3.10
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ (2008) 2.98
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Gene variants associated with deep vein thrombosis. JAMA (2008) 2.74
Aspirin as an antiplatelet drug. N Engl J Med (1994) 2.72
Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem (2007) 2.56
Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J (2006) 2.40
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis (2007) 2.12
A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res (2005) 2.05
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J (2009) 1.92
Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J (2007) 1.78
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol (2008) 1.71
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol (2009) 1.57
Proof of principle of potential clinical utility of multiple SNP analysis for prediction of recurrent venous thrombosis. J Thromb Haemost (2008) 1.53
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics (2008) 1.52
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res (2006) 1.43
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics (2009) 1.41
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther (2008) 1.40
Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am (2007) 1.29
Genetic variants associated with deep vein thrombosis: the F11 locus. J Thromb Haemost (2009) 1.24
Molecular basis of vitamin K-dependent gamma-carboxylation. Blood (1990) 1.20
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol (2009) 1.16
Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther (2003) 1.10
One hundred years of aspirin. Lancet (1997) 1.07
Protein C and protein S deficiencies. Semin Hematol (1997) 1.04
Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost (2005) 1.04
VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood (2008) 1.00
Polymorphisms in the protein C gene as risk factor for venous thrombosis. Thromb Haemost (2009) 0.98
Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics (2007) 0.98
Clopidogrel, genetics, and drug responsiveness. N Engl J Med (2009) 0.97
Genetic variation in fibrinogen; its relationship to fibrinogen levels and the risk of myocardial infarction and ischemic stroke. J Thromb Haemost (2009) 0.97
A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. J Thromb Thrombolysis (2005) 0.97
The genetics of antiplatelet drug resistance. Clin Genet (2008) 0.93
Protease-activated receptors as targets for antiplatelet therapy. Blood Rev (2008) 0.92
Prevalence of the G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in different human populations. Acta Haematol (1998) 0.91
Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis (2002) 0.90
Thrombophilias: when should we test and how does it help? Semin Respir Crit Care Med (2008) 0.90
Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. J Clin Chem Clin Biochem (1990) 0.89
Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics (2007) 0.88
Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol (2007) 0.87
Antiplatelet therapy: Personalized medicine for clopidogrel resistance? Nat Rev Cardiol (2009) 0.87
Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost (1998) 0.84
Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations. Clin Appl Thromb Hemost (2006) 0.83
Who should be tested for thrombophilia? Curr Opin Hematol (2006) 0.82
Factor V Leiden, prothrombin 20210G-->A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost (1999) 0.81
Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors. Blood Coagul Fibrinolysis (2005) 0.79
Clopidogrel pharmacogenetics and its clinical implications. Am J Ther (2010) 0.78
Current practise of testing for inherited thrombophilia. J Thromb Haemost (2007) 0.78
The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost (2008) 0.77
FDA advisory committee meeting on prasugrel for acute coronary syndromes. P T (2009) 0.77
Hereditary and acquired antithrombin deficiency. Semin Thromb Hemost (1999) 0.76
Detection of microRNA expression in human peripheral blood microvesicles. PLoS One (2008) 8.04
Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int (2011) 4.51
Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med (2008) 3.59
Body mass index is independently associated with hospital mortality in mechanically ventilated adults with acute lung injury. Crit Care Med (2006) 3.38
Glucose variability and mortality in patients with sepsis. Crit Care Med (2008) 3.00
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal (2009) 2.57
Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients. Crit Care Med (2007) 2.42
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci U S A (2008) 2.24
Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med (2013) 2.16
Caspase-7 activation by the Nlrc4/Ipaf inflammasome restricts Legionella pneumophila infection. PLoS Pathog (2009) 1.99
The association of prior cytomegalovirus infection with neovascular age-related macular degeneration. Am J Ophthalmol (2004) 1.95
Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice. Crit Care Med (2006) 1.92
Analysis of the molecular quality of human tissues: an experience from the Cooperative Human Tissue Network. Am J Clin Pathol (2002) 1.92
Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood (2012) 1.80
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood (2012) 1.73
Microarray analysis of human monocytes infected with Francisella tularensis identifies new targets of host response subversion. PLoS One (2008) 1.67
Activation of estrogen receptor-alpha reduces aortic smooth muscle differentiation. Circ Res (2006) 1.63
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal (2008) 1.60
The association between body mass index, processes of care, and outcomes from mechanical ventilation: a prospective cohort study. Crit Care Med (2012) 1.60
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun (2009) 1.58
Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res (2009) 1.57
MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced pro-inflammatory cytokine response. PLoS One (2009) 1.55
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br J Haematol (2012) 1.52
The role of the NADPH oxidase complex, p38 MAPK, and Akt in regulating human monocyte/macrophage survival. Am J Respir Cell Mol Biol (2006) 1.52
M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol (2003) 1.50
Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.46
Characterization of a preclinical model of chronic ischemic wound. Physiol Genomics (2009) 1.38
Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol (2006) 1.37
Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med (2014) 1.34
In vivo monitoring of pH, redox status, and glutathione using L-band EPR for assessment of therapeutic effectiveness in solid tumors. Magn Reson Med (2011) 1.33
The inositol 3-phosphatase PTEN negatively regulates Fc gamma receptor signaling, but supports Toll-like receptor 4 signaling in murine peritoneal macrophages. J Immunol (2004) 1.31
Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis (2002) 1.31
The acute respiratory distress syndrome: a role for transforming growth factor-beta 1. Am J Respir Cell Mol Biol (2003) 1.28
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica (2010) 1.27
GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity (2004) 1.23
How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood (2014) 1.21
Integrating the MicroRNome into the study of lung disease. Am J Respir Crit Care Med (2008) 1.19
Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. PLoS One (2013) 1.18
MicroRNAs in the pathogenesis of Lung Cancer. J Thorac Oncol (2009) 1.17
Lipopolysaccharide-induced macrophage inflammatory response is regulated by SHIP. J Immunol (2004) 1.17
Toward a fully de-identified biomedical information warehouse. AMIA Annu Symp Proc (2009) 1.14
The inositol 5'-phosphatase SHIP-1 and the Src kinase Lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity. J Biol Chem (2003) 1.12
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer (2007) 1.11
Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol (2004) 1.11
Trityl-based EPR probe with enhanced sensitivity to oxygen. Free Radic Biol Med (2009) 1.11
M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS One (2008) 1.11
Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum Immunol (2006) 1.10
Program in pharmacogenomics at the Ohio State University Medical Center. Pharmacogenomics (2012) 1.07
Asc-dependent and independent mechanisms contribute to restriction of legionella pneumophila infection in murine macrophages. Front Microbiol (2011) 1.06
The role of ROS and RNS in regulating life and death of blood monocytes. Curr Pharm Des (2004) 1.06
Thrombospondin-1-deficient mice are not protected from bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol (2010) 1.06
Distinct proteome features of plasma microparticles. Proteomics (2005) 1.05
Macrophage-colony-stimulating factor-induced activation of extracellular-regulated kinase involves phosphatidylinositol 3-kinase and reactive oxygen species in human monocytes. J Immunol (2002) 1.05
TGF-beta 1 suppresses [correction of supresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit. J Immunol (2003) 1.05
sRAGE induces human monocyte survival and differentiation. J Immunol (2010) 1.05
Proteome comparison of alveolar macrophages with monocytes reveals distinct protein characteristics. Am J Respir Cell Mol Biol (2004) 1.03
Social disruption induces lung inflammation. Brain Behav Immun (2009) 1.02
Opposing roles for HIF-1α and HIF-2α in the regulation of angiogenesis by mononuclear phagocytes. Blood (2010) 1.02
The expression of the cytomegalovirus chemokine receptor homolog US28 sequesters biologically active CC chemokines and alters IL-8 production. Cytokine (2002) 1.01
Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity. PLoS One (2011) 1.01
Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol (2007) 1.00
Monocyte survival factors induce Akt activation and suppress caspase-3. Am J Respir Cell Mol Biol (2002) 1.00
Human cytomegalovirus disrupts constitutive MHC class II expression. J Immunol (2002) 0.99
Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol (2008) 0.99
Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis. J Immunol (2011) 0.98
Latency associated peptide has in vitro and in vivo immune effects independent of TGF-beta1. PLoS One (2008) 0.98
Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells. Biochem J (2004) 0.96
Human cytomegalovirus protein pp71 disrupts major histocompatibility complex class I cell surface expression. J Virol (2006) 0.96
The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod Pathol (2011) 0.96
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. Clin Cancer Res (2010) 0.96
Src homology 2 domain-containing inositol polyphosphate phosphatase regulates NF-kappa B-mediated gene transcription by phagocytic Fc gamma Rs in human myeloid cells. J Immunol (2002) 0.94
An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol (2006) 0.94
Cucurbitacin B induces rapid depletion of the G-actin pool through reactive oxygen species-dependent actin aggregation in melanoma cells. Acta Biochim Biophys Sin (Shanghai) (2011) 0.93
Mesenchymal stem cells for cardiac regeneration: translation to bedside reality. Stem Cells Int (2012) 0.92
Vitamin C-induced activation of phospholipase D in lung microvascular endothelial cells: regulation by MAP kinases. Cell Signal (2006) 0.91
SHIP2 is recruited to the cell membrane upon macrophage colony-stimulating factor (M-CSF) stimulation and regulates M-CSF-induced signaling. J Immunol (2004) 0.91
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther (2013) 0.91
Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol (2010) 0.91
Negative regulators of toll-like receptor 4-mediated macrophage inflammatory response. Curr Pharm Des (2006) 0.91
Toward functional proteomics of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol (2005) 0.91
ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy. Br J Haematol (2011) 0.90
Phospholipase A2 activation regulates cytotoxicity of methylmercury in vascular endothelial cells. Int J Toxicol (2007) 0.90
Mercury activates vascular endothelial cell phospholipase D through thiols and oxidative stress. Int J Toxicol (2007) 0.89
Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion (2014) 0.89
Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. Eur J Intern Med (2013) 0.89
M-CSF induces monocyte survival by activating NF-κB p65 phosphorylation at Ser276 via protein kinase C. PLoS One (2011) 0.88
The protein-tyrosine phosphatase SHP-1 associates with the phosphorylated immunoreceptor tyrosine-based activation motif of Fc gamma RIIa to modulate signaling events in myeloid cells. J Biol Chem (2003) 0.88
Two-dimensional gel proteome reference map of blood monocytes. Proteome Sci (2006) 0.88
Using an agent-based model to analyze the dynamic communication network of the immune response. Theor Biol Med Model (2011) 0.87
Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment. Acta Biochim Biophys Sin (Shanghai) (2011) 0.87
The inositol phosphatase SHIP-2 down-regulates FcgammaR-mediated phagocytosis in murine macrophages independently of SHIP-1. Blood (2005) 0.87
Opposing effect by cytokines on Fas-mediated apoptosis in A549 lung epithelial cells. Am J Respir Cell Mol Biol (2002) 0.86
Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol (2012) 0.86
Hyperglycemic oxoaldehyde, glyoxal, causes barrier dysfunction, cytoskeletal alterations, and inhibition of angiogenesis in vascular endothelial cells: aminoguanidine protection. Mol Cell Biochem (2009) 0.85